All In Biotech

Free tool

FAERS Monitor: Zerbaxa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206829 or its brand name (Zerbaxa, Ceftolozane Sulfate, Tazobactam Sodium). Reports on generic versions are filed under their own applications.

Reports

982

Serious

670

68% of reports

Hospitalization

274

Death reported

233

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use139
  • product use in unapproved indication128
  • no adverse event90
  • death81
  • product use issue67
  • pathogen resistance54
  • drug ineffective44
  • acute kidney injury36
  • drug resistance30
  • encephalopathy27
  • incorrect dose administered26
  • pancytopenia26
  • pneumonia26
  • renal failure25
  • septic shock25

Reports by year received

View as table
YearReports
201545
201685
2017126
2018135
2019126
2020145
202142
202255
202382
202467
202549
202625

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,177 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pathogen resistanceSignal54127.698.46,622
drug resistanceSignal3025.017.6669
encephalopathySignal2723.616.2561
septic shockSignal2512.38.4249
product use in unapproved indicationSignal12811.19.41,175
no adverse eventSignal9010.68.7783
pancytopeniaSignal2610.06.8201
product use issueSignal677.66.1383
acute kidney injurySignal365.03.7113
renal failureSignal254.02.754
off label useSignal1393.42.9243
incorrect dose administeredSignal262.41.721
deathSignal812.01.642
pneumonia261.71.27
drug ineffective440.70.55

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.